Clinical Trial Update: A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating dasatinib as first-line therapy for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Phase Chronic Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Chronic Myelogenous Leukemia - Chronic Phase | Phase 4 | Status: COMPLETED